Reply

Alfred H.J. Kim; Vibeke Strand; John P. Atkinson

doi:10.1002/art.40923

Reply

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1590-1592
Number of pages	3
Journal	Arthritis and Rheumatology
Volume	71
Issue number	9
DOIs	https://doi.org/10.1002/art.40923
State	Published - Sep 1 2019

Access to Document

10.1002/art.40923

Cite this

@article{50ea584a83b2483485e249a80c110c51,

title = "Reply",

author = "Kim, \{Alfred H.J.\} and Vibeke Strand and Atkinson, \{John P.\}",

note = "Funding Information: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Supported by the NIH (grant R21-AR-069833 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases) and Kypha, Inc. Dr. Kim has received consulting fees, speaking fees, and/or honoraria from Exagen Diagnostics and has served as a member of their Advisory Board (less than \$10,000). Dr. Strand has received consulting fees from Kypha, Inc., AbbVie, Amgen, AstraZeneca PLC, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech/Roche Holding AG, GlaxoSmithKline, Janssen, Eli Lilly and Company, Novartis International AG, Pfizer, and UCB (less than \$10,000 each). Dr. Atkinson has received consulting fees from and has served on the Advisory Boards of Kypha, Inc., Compliment Corporation, Gemini Therapeutics, Celldex Therapeutics, Clinical Pharmacy Services, CDMI, Ome-ros Corporation, Achillion Pharmaceuticals, True North Therapeutics, BioMarin Pharmaceutical, Annexon Biosciences, and AdMiRx (less than \$10,000 each).",

year = "2019",

month = sep,

day = "1",

doi = "10.1002/art.40923",

language = "English",

volume = "71",

pages = "1590--1592",

journal = "Arthritis and Rheumatology",

issn = "2326-5191",

number = "9",

}

TY - JOUR

T1 - Reply

AU - Kim, Alfred H.J.

AU - Strand, Vibeke

AU - Atkinson, John P.

N1 - Funding Information: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Supported by the NIH (grant R21-AR-069833 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases) and Kypha, Inc. Dr. Kim has received consulting fees, speaking fees, and/or honoraria from Exagen Diagnostics and has served as a member of their Advisory Board (less than $10,000). Dr. Strand has received consulting fees from Kypha, Inc., AbbVie, Amgen, AstraZeneca PLC, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Genentech/Roche Holding AG, GlaxoSmithKline, Janssen, Eli Lilly and Company, Novartis International AG, Pfizer, and UCB (less than $10,000 each). Dr. Atkinson has received consulting fees from and has served on the Advisory Boards of Kypha, Inc., Compliment Corporation, Gemini Therapeutics, Celldex Therapeutics, Clinical Pharmacy Services, CDMI, Ome-ros Corporation, Achillion Pharmaceuticals, True North Therapeutics, BioMarin Pharmaceutical, Annexon Biosciences, and AdMiRx (less than $10,000 each).

PY - 2019/9/1

Y1 - 2019/9/1

UR - https://www.scopus.com/pages/publications/85069843874

U2 - 10.1002/art.40923

DO - 10.1002/art.40923

M3 - Letter

C2 - 31074940

AN - SCOPUS:85069843874

SN - 2326-5191

VL - 71

SP - 1590

EP - 1592

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

IS - 9

ER -

Reply

Access to Document

Other files and links

Cite this